title: CRISPR/Cas9 Genome Editing as a Strategy to Study the Tumor Microenvironment in Transgenic Mice.
abstract: Development of engineered site-specific endonucleases like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas9 has been revolutionizing genetic approaches in biomedical research fields. These new tools have opened opportunities to carry out targeted genome editing in mouse zygotes without the need for manipulating embryonic stem cells, which have a higher technical burden and many constraints in strain availability. Specific genetic modifications can be directly generated in working genetic backgrounds. This new approach saves time and costs associated with generation and backcrossing of genetically modified animals and will facilitate their use in various cancer research fields.
authors: GCRC Transgenic Facility, Department of Human Genetics, Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, rm419, Montreal, QC, Canada, H3A1A3. yojiro.yamanaka@mcgill.ca.
authors: Yojiro
authors: Y
authors: Yamanaka
mesh_terms: D000818:Animals; D064113:CRISPR-Cas Systems; D053903:DNA Breaks, Double-Stranded; D004260:DNA Repair; D004195:Disease Models, Animal; D000072669:Gene Editing; D005838:Genotype; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D000094704:RNA, Guide, CRISPR-Cas Systems; D059016:Tumor Microenvironment
chemical_list: D000094704:RNA, Guide, CRISPR-Cas Systems
keywords: Blastocysts; CRISPR/Cas9; Double strand DNA breaks (DSBs); Homology directed repair (HDR); Mouse zygotes; Nonhomologous end joining (NHEJ); sgRNAs